Monopar Therapeutics (MNPR) Cash & Equivalents (2016 - 2025)

Monopar Therapeutics (MNPR) has 10 years of Cash & Equivalents data on file, last reported at $61.8 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 34.96% year-over-year to $61.8 million; the trailing twelve-month figure through Dec 2025 stood at $61.8 million (up 34.96% YoY), and the FY2025 full-year result was $61.8 million, up 34.96% from the prior year.
• Cash & Equivalents retreated to $61.8 million in Q4 2025, from $127.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $127.7 million in Q3 2025 to a low of $5.5 million in Q3 2023.
• A 5-year average of $25.7 million and a median of $17.1 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents sank 60.39% in 2023 and soared 2020.86% in 2025, its largest moves.
• Tracing MNPR's Cash & Equivalents over 5 years: stood at $20.0 million in 2021, then sank by 59.1% to $8.2 million in 2022, then declined by 11.24% to $7.3 million in 2023, then soared by 530.55% to $45.8 million in 2024, then soared by 34.96% to $61.8 million in 2025.
• Business Quant data shows MNPR's Cash & Equivalents at $61.8 million in Q4 2025, $127.7 million in Q3 2025, and $39.5 million in Q2 2025.